While the role of LncRNAs in the protective effect of GLP-1R agonists in steatosis has not been researched in vivo, there is ample evidence that these drugs do reduce fat liver content both in NAFLD patients and animal models. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.